Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06385886 · ClinicalTrials.gov registry record

Recruitment and Engagement in Care to Impact Practice Enhancement (RECIPE) for Sickle Cell Disease

A clinical trial of Sickle Cell Disease, sponsored by RTI International.

Recruiting
Registry status
500
Enrollment target
9
Study locations

NCT06385886: Recruiting study of Sickle Cell Disease, sponsored by RTI International.

NCT06385886 is a study of Sickle Cell Disease that is actively recruiting participants, run by RTI International. The registered enrollment target is 500 participants, above the 290-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (72% higher). The trial reports 9 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06385886, a study of Sickle Cell Disease, is actively recruiting participants, sponsored by RTI International.

RECRUITING
Registry status
500 participants
Enrollment target
9
Study locations

Study Summary

The goal of this observational study is to help us understand more about the best ways to help individuals living with Sickle Cell Disease (SCD) get the best care. The main question it aims to answer is: How to find individuals unaffiliated from SCD specialist care use three distinct pathways? Once unaffiliated individuals are found using the pathways, Investigators will employ linkage coordinators (trained staff) to engage these patients in care. Participants will be asked to fill out an assessment survey which will cover areas such as previous and current treatment, clinic and hospital experience, pain, and quality of life. Participants will also be given the option of participation in a 1-hour long interview how they feel about treatment for sickle cell disease including clinic experience, pain, and quality of life?

Primary Outcome

Identification of patients through hospital, surveillance, and community-based pathways.

Conditions Studied

Sickle Cell Disease

Interventions

  • BEHAVIORAL Linkage Coordinator

Study Locations (9)

Alabama

  • University of Alabama, Birmingham (UAB) - Birmingham

Arizona

  • Phoenix Children's Hospital - Phoenix

California

  • University of California, San Francisco (UCSF) - Oakland

Georgia

  • Augusta University - Augusta

Illinois

  • University of Illinois - Chicago

Ohio

  • Cleveland Clinic - Cleveland

Pennsylvania

  • University of Pennsylvania - Philadelphia

Tennessee

  • University of Tennessee at Memphis - Memphis

Trial Details

FieldValue
Enrollment Target 500 participants
Start Date 2023-06-08
Est. Completion 2027-12
RTI International

45 total trials

What NCT06385886 shows while recruiting

NCT06385886 is an observational study that tracks outcomes without assigning an intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap, above the 290-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (72% higher).

The record links to 1 condition, with Sickle Cell Disease appearing as the primary indexed condition, and to 1 intervention - of which Linkage Coordinator is the first listed.

NCT06385886 lists 9 locations in 9 states (Alabama, Arizona, California).

Frequently Asked Questions

What is clinical trial NCT06385886 about?

NCT06385886 is a clinical study titled "Recruitment and Engagement in Care to Impact Practice Enhancement (RECIPE) for Sickle Cell Disease". The goal of this observational study is to help us understand more about the best ways to help individuals living with Sickle Cell Disease (SCD) get the best care. The main question it aims to answer is: How to find individuals unaffiliated from SCD specialist care use three distinct pathways? Once ...

What is the current status of trial NCT06385886?

This trial is currently recruiting. The enrollment target is 500 participants. The study started on 2023-06-08. Estimated completion is 2027-12.

What conditions does trial NCT06385886 study?

This clinical trial studies the following conditions: Sickle Cell Disease.

What interventions are being tested in trial NCT06385886?

The interventions under investigation include: Linkage Coordinator (BEHAVIORAL).

Who is sponsoring clinical trial NCT06385886?

This trial is sponsored by RTI International, which has 45 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06385886 being conducted?

This trial has 9 study locations across Alabama, Arizona, California, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Sickle Cell Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06385886's enrollment target sits among peer trials

500 6th of 213 higher than 208 of 213 other Sickle Cell Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Sickle Cell Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00001230 · 500 participants

    Host Response to Infection and Treatment in Filarial Diseases

  • NCT00001529 · 500 participants

    Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives

  • NCT00697411 · 500 participants

    Study of Selected X-Linked Disorders: Aicardi Syndrome

  • NCT00903110 · 500 participants

    Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT06385886

Source: ClinicalTrials.gov NCT06385886, the US trial registry maintained by the National Library of Medicine. NCT06385886 (mid enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.